Prague Med. Rep. 2015, 116, 253-267
https://doi.org/10.14712/23362936.2015.65
Pancreatic Cancer Diagnostics and Treatment – Current State
References
1. American Cancer Society (2013) Cancer Facts and Figures 2013. ACS, Atlanta.
2. , A. E., Hernandez, Y. G., Krucht, H., Lucas, A. L. (2014) Pancreatic ductal adenocarcinoma: Risk factors, screening, and early detection. World J. Gastroenterol. 20(32), 11182–11198.
<https://doi.org/10.3748/wjg.v20.i32.11182>
<PubMed>
3. , M., Uzunoglu, F. G., Adham, M., Imrie, C., Milicevic, M., Sandberg, A. A., Asbun, H. J., Bassi, C., Büchler, M., Charnley, R. M., Conlon, K., Cruz, L. F., Dervenis, Ch., Fingerhutt, A., Friess, H., Gouma, D. J., Hartwig, W., Lillemoe, K. D., Montorsi, M., Neoptolemos, J. P., Shrikhande, S. V., Takaori, K., Traverso, W., Vashist, Y. K., Vollmer, C., Yeo, C. J., Izbicki, J. R. (2014) Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery 155, 977–988.
<https://doi.org/10.1016/j.surg.2014.02.001>
4. , B. A., Steve, J., Krasinskas, A. M., Zureikat, A. H., Lembersky, B. C., Gibson, M. K., Stoller, R. G., Zeh, H. J., Bahary, N. (2013) Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. J. Surg. Oncol. 108(4), 236–241.
<https://doi.org/10.1002/jso.23392>
<PubMed>
5. , M. I., Harinck, F., Hruban, R. H., Offerhaus, G. J., Poley, J. W., Kamel, I., Nio, Y., Schulick, R. S., Bassi, C., Kluijt, I., Levy, M. J., Chak, A., Fockens, P., Goggins, M., Bruno, M. (2013) International Cancer of the Pancreas Screening (CAPS) Consorcium Summit on the management of patients with increased risk for familial pancreatic cancer. Gut 62, 339–347.
<https://doi.org/10.1136/gutjnl-2012-303108>
<PubMed>
6. , T., Gavoille, C., Samalin, E., Ychou, M., Ducreux, M. (2013) The role of the FOLFIRINOX regimen for advanced pancreatic cancer. Curr. Oncol. Rep. 15, 182–189.
<https://doi.org/10.1007/s11912-012-0290-4>
7. , Y., Hanoun, N., Lulka, H., Sicard, F., Selves, J., Buscail, L., Torrisani, J., Cordelier, P. (2011) Genetic and epigenetic alterations in pancreatic carcinogenesis. Curr. Genomics 12, 15–24.
<https://doi.org/10.2174/138920211794520132>
<PubMed>
8. Diener, M. K., Fitzmaurice, C., Schwarzer, G., Seiler, C. M., Antes, G., Knaebel, H. P., Büchler, M. W. (2014) Pylorus-preserving pancreaticoduodenectomy (pp Whipple) versus pancreaticoduodenectomy (classic Whipple) for surgical treatment of periampullary and pancreatic carcinoma. Cochrane Database Syst. Rev. 11, CD006053.
9. , M., Eibl, G. (2014) Risk factors for pancreatic cancer: underlying mechanisms and potential targets. Front. Physiol. 5, 490.
<https://doi.org/10.3389/fphys.2014.00490>
<PubMed>
10. , V. L., Gukovskaya, A., Pandol, S. J. (2005) Alcohol and pancreatic cancer. Alcohol 35(3), 205–211.
<https://doi.org/10.1016/j.alcohol.2005.03.010>
11. , K. S., Yao, X., Cong, X., Thumar, J. R., Hochster, H. S., Stein, S. M., Lacy, J. (2013) FOLFIRINOX for locally advanced and metastatic pancreatic cancer: Single institution retrospective review of efficacy and toxicity. Med. Oncol. 30(1), 361.
<https://doi.org/10.1007/s12032-012-0361-2>
12. , C. J., Moyer, M. T., Saif, M. W. (2009) Biomarkers for early detection and screening in pancreatic cancer. JOP 10(4), 352–356.
13. , P. J., Macintyre, J., Kawamura, C., Maldonado, J. C., Ernani, V., Loaiza-Bonilla, A., Narayanan, G., Ribeiro, A., Portelance, L., Merchan, J. R., Levi, J. U., Rocha-Lima, C. M. (2012) A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer 12, 199.
<https://doi.org/10.1186/1471-2407-12-199>
<PubMed>
14. , D., Krška, Z., Hořejš, J. (2014) Pokročilý karcinom hlavy pankreatu – chirurgické možnosti. Pancreatic Cancer News 1(2), 16–18.
15. , R. H., Goggins, M., Parsons, J., Kern, S. E. (2000) Progression model for pancreatic cancer. Clin. Cancer Res. 6, 2969–2972.
16. , R. H., Canto, M., Goggins, M., Schulick, R., Klein, A. P. (2010) Update on familial pancreatic cancer. Adv. Surg. 44, 293–311.
<https://doi.org/10.1016/j.yasu.2010.05.011>
17. Kelsen, D. P., Tepper, J. E., Levin, B., Kern, S. E., Daly, J. M. (2008) Principles and Practice of Gastrointestinal Oncology, 2nd Edition. Lippincott Williams and Wilkins, Philadelphia.
18. , T., Shugrue, C., Ashat, M., Thrower, E. C. (2014) Risk factors for pancreatic cancer: underlying mechanisms and potential targets. Front. Physiol. 4, 415.
<https://doi.org/10.3389/fphys.2013.00415>
<PubMed>
19. , Z. (2014a) Aktuální chirurgie pankreatu. Pancreatic Cancer News 1(2), 8–12.
20. , Z. (2014b) Strobel, O., Büchler, M. W.: Borderline-Resektabilität beim Pankreaskarzinom: Konsensus-Statement der ISGPS. Překlad a komentář. Pancreatic Cancer News 1(2), 15.
21. Krška, Z., Hoskovec, D., Petruželka, L. (2014) Chirurgická Onkologie. Grada, Prague.
22. , J. L., Kim, S. C., Kim, J. H., Lee, S. S., Kim, T. W., Park, do H., Seo, D. W., Lee, S. K., Kim, M. H., Kim, J. H., Park, J. H., Shin, S. H., Han, D. J. (2012) Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma. Surgery 152(5), 851–862.
<https://doi.org/10.1016/j.surg.2012.03.010>
23. , H. T., Fitzsimmons, M. L., Smyrk, T. C., Lanspa, S. J., Watson, P., McClellan, J., Lynch, J. F. (1990) Familial pancreatic cancer: clinicopathologic study of 18 nuclear families. Am. J. Gastroenterol. 85, 54–60.
24. , R. P., Kramer, P. (1973) Adenocarcinoma of the pancreas in four siblings. Gastroenterology 65, 137–139.
<https://doi.org/10.1016/S0016-5085(19)33156-7>
25. , R. (2015) Phenome-genome association studies of pancreatic cancer: new targets for therapy and diagnosis. Cancer Genomics Proteomics 12, 9–19.
26. , S. N., Bloomston, M., Schmidt, C. M., Ellison, E. C., Muscarella, P. (2014) Biomarkers as predictors of recurrence following curative resection for pancreatic ductal adenocarcinoma: a review. Biomed. Res. Int. 2014, 468959.
<https://doi.org/10.1155/2014/468959>
<PubMed>
27. , U., Klein, F., Bahra, M., Sinn, M., Dörken, B., Neuhaus, P., Meyer, O., Riess, H. (2013) Blood group determinates incidence for pancreatic cancer in Germany. Front. Physiol. 4, 118.
<https://doi.org/10.3389/fphys.2013.00118>
<PubMed>
28. , U., Sinn, M., Stieler, J., Riess, H. (2014) Multimodal treatment of pancreatic cancer. Internist (Berl.) 55(1), 31–36.
<https://doi.org/10.1007/s00108-013-3316-6>
29. , J., Egan, K. M. (2009) Family history is a significant risk factor for pancreatic cancer: results from a systematic review and meta-analysis. Fam. Cancer 8, 109–117.
<https://doi.org/10.1007/s10689-008-9214-8>
30. , L. (2014) Systémová léčba metastazujících karcinomů slinivky břišní – kdy, jak a pro koho? Pancreatic Cancer News 1, 20–26.
31. , R., Hendifar, A. E., Tuli, R. (2014) Genetic determinants and potential therapeutic targets for pancreatic adenocarcinoma. Front. Physiol. 5, 87.
<https://doi.org/10.3389/fphys.2014.00087>
<PubMed>
32. , R., Ward, E., Brawley, O., Jemal, A. (2011) Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin. 61(4), 212–236.
<https://doi.org/10.3322/caac.20121>
33. , A. S., Syrigos, K. N., Saif, M. W. (2010) Translational research in pancreatic cancer. JOP 11(2), 124–127.
34. , O., Büchler, M. W. (2014) Borderline-Resektabilität beim Pankreaskarzinom: Konsensus-Statement der ISGPS. Chirurg 85, 1014.
<https://doi.org/10.1007/s00104-014-2902-z>
